EMAIL THIS PAGE TO A FRIEND

Haemophilia : the official journal of the World Federation of Hemophilia

Inflammatory focal bone destruction in femoral heads with end-stage haemophilic arthropathy: a study on clinic samples with micro-CT and histological analyses.


PMID 26388304

Abstract

Focal bone destruction has a high prevalence in haemophilic arthropathy (HA) affected joints, but the mechanism remains unclear. We undertook this study on clinic samples to explore the focal bone destruction in femoral heads suffered with end-stage HA. Twenty-one femoral heads from HA patients and 19 femoral heads from rheumatoid arthritis (RA) patients were scanned by micro-CT. Histological analysis, including TRAP staining of subchondral bone were performed to evaluate the bone destruction and osteoclasts activity. RANKL, OPG as well as pro-inflammatory cytokines, such as TNF-α and IL-1β in subchondral bone were detected by immunohistochemistry (IHC) method. Severe focal lesion was observed in all the HA and RA femoral heads by micro-CT imaging and histological analysis. The mean percentage of lesion volume to total volume of the femoral heads from HA patients was significantly higher than those from RA patients. There was no significant difference in osteoclasts numbers in subchondral bone between HA and RA groups. By IHC analysis, high expression of RANKL, TNF-α, IL-1β and low expression of OPG and RANK were observed in subchondral bone, and there were no significant differences in the expression of RANKL, OPG, RANK, TNF-α and IL-1β in femoral heads derived from HA and RA patients. Our findings demonstrated the focal bone destruction coupled with inflammatory osteoclastogenesis at subchondral bone in femoral heads from patients with end-stage HA, and that was similar to the changes in the femoral heads of RA patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

O1139 Anti-Osteoprotegerin antibody produced in goat, affinity isolated antibody, lyophilized powder
O7262 Anti-Osteoprotegerin antibody produced in goat, affinity isolated antibody
HPA027728
Anti-TNFRSF11A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406202
Anti-TNFRSF11B antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA027013
Anti-TNFRSF11B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410859
Anti-TNFRSF11B antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1409922
Anti-TNFSF11 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4503430
Anti-TNFSF11 antibody produced in rabbit, affinity isolated antibody
SAB1411542
Anti-TNFSF11 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB5300009
Monoclonal Anti-TNFRSF11B antibody produced in mouse, clone 5G2, ascites fluid
SAB5300010
Monoclonal Anti-TNFRSF11B antibody produced in mouse, clone 5A11, ascites fluid
SAB1402993
Monoclonal Anti-TNFSF11, (C-terminal) antibody produced in mouse, clone 3F7, purified immunoglobulin, buffered aqueous solution
T2942 Monoclonal Anti-TRANCE antibody produced in mouse, clone 70525, purified immunoglobulin, lyophilized powder